How should a rash that develops in a patient taking leflunomide be evaluated and managed?

Leflunomide Drug Rash: Evaluation and Management

If a patient on leflunomide develops a rash, immediately discontinue the drug and initiate cholestyramine washout (8 grams three times daily for 11 days) to rapidly eliminate the active metabolite, particularly if there are any signs of severe cutaneous reactions, systemic symptoms, or mucosal involvement. 1

Initial Assessment

When evaluating a leflunomide-associated rash, determine the severity and type:

Mild Cutaneous Reactions

• Common presentations: Simple maculopapular rash, pruritus, dry skin, eczema (occur in ~10% of patients) 2
• Management: May continue drug with close monitoring if rash is mild and isolated
• Monitoring: Weekly assessment until resolution or progression is determined

Severe Cutaneous Reactions - IMMEDIATE DISCONTINUATION REQUIRED

Stop leflunomide immediately if any of the following are present:

• Bullous lesions or skin blistering 3, 4
• Mucosal involvement (oral ulcers, conjunctivitis, genital lesions) 4
• Widespread erythema covering >30% body surface area 3, 5
• Systemic symptoms: Fever, facial edema, lymphadenopathy 6, 5
• Target-like lesions suggesting erythema multiforme 7
• Annular or polycyclic plaques in photodistributed areas (subacute cutaneous lupus erythematosus pattern) 7, 8
• Lichenoid eruption with nail dystrophy 9

Specific Severe Reactions to Recognize

Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

• Reported rarely but can be fatal 1, 4
• Presents with progressive blistering, epidermal detachment, and mucosal erosions
• Requires immediate hospitalization, burn unit care, and aggressive drug elimination 4

DRESS Syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms)

• Delayed onset (typically 4-6 weeks after starting drug) 6, 5
• Key features: Fever, facial edema, widespread rash, eosinophilia (>1000/mm³), hepatosplenomegaly, lymphadenopathy 6
• Organ involvement: Liver injury (elevated transaminases), renal dysfunction, pulmonary infiltrates 6, 5
• RegiSCAR score ≥5 confirms diagnosis 6

Drug-Induced Subacute Cutaneous Lupus Erythematosus

• Annular or papulosquamous plaques in sun-exposed areas 7, 8
• May have positive anti-Ro/SSA antibodies
• Reversible with drug discontinuation 8

Mandatory Drug Elimination Procedure

The FDA label explicitly requires cholestyramine washout for any serious toxicity, including severe rash 1:

1. Cholestyramine 8 grams orally three times daily for 11 days (days need not be consecutive)
2. Verify plasma M1 metabolite levels <0.02 mg/L by two separate tests at least 14 days apart
3. If levels remain elevated, repeat cholestyramine treatment
4. Alternative: Activated charcoal 50 grams every 6 hours for 24 hours (reduces M1 by 48% in 48 hours) 1

Without washout, the active metabolite may persist for up to 2 years due to enterohepatic recirculation 1

Laboratory Evaluation

Obtain immediately when severe rash develops:

• Complete blood count with differential (assess for eosinophilia, pancytopenia) 10
• Liver function tests (ALT, AST, bilirubin) - hepatotoxicity occurs in 4-8% 2
• Renal function (creatinine, BUN)
• If DRESS suspected: Atypical lymphocytes, elevated IgE, viral serologies (EBV, HHV-6)

Supportive Treatment

For Severe Cutaneous Reactions:

• Systemic corticosteroids: Methylprednisolone 1-2 mg/kg/day or equivalent 3, 4
• Duration: Taper over 4-6 weeks as skin lesions resolve
• IVIG: Consider for TEN/SJS (reported effective in one case) 3
• Topical corticosteroids: For localized lesions in drug-induced SCLE 8

Monitoring During Recovery:

• Daily assessment of skin progression/improvement
• Repeat CBC and LFTs every 2-3 days until normalizing
• Ophthalmology consultation if ocular involvement (keratitis can cause permanent vision loss) 4

Critical Pitfalls to Avoid

1. Do not rechallenge with leflunomide after severe cutaneous reaction - risk of recurrence is high 6
2. Do not delay washout procedure - the long half-life (weeks to months) prolongs toxicity 1
3. Do not assume mild rash is benign - severe reactions can evolve from initially mild presentations 3, 5
4. Monitor for late-onset reactions - DRESS can occur 4-6 weeks after starting therapy 6, 5
5. Screen for hepatotoxicity concurrently - liver injury often accompanies severe cutaneous reactions 6, 5

Special Considerations

Patients with multiple risk factors require heightened vigilance:

• Recent or concurrent methotrexate use (increases risk of severe reactions) 2, 1
• Pre-existing autoimmune conditions (may trigger lupus-like syndromes) 7, 8
• Pediatric patients (nail dystrophy may be prominent feature) 9

The 2020 AAD/NPF guidelines emphasize monthly monitoring of CBC and LFTs for the first 6 months specifically to detect early toxicity signals 10, which should prompt immediate evaluation if rash develops during this period.